{
    "id": "item-1762343631623-stpqup",
    "type": "agent",
    "x": 4260,
    "y": -4540,
    "width": 520,
    "height": 800,
    "content": "# Question\nSarah Miller, a 63-year-old female with a history of rheumatoid arthritis treated with methotrexate 20mg weekly since 2015, hypertension managed with lisinopril 10mg daily, and mild chronic kidney disease, presented to the emergency department with a 24-hour history of jaundice, confusion, and epigastric pain. She had been started on trimethoprim-sulfamethoxazole 800/160mg BID six days prior for acute bacterial sinusitis. Lab results revealed ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and direct bilirubin 8.9 mg/dL. What is the DILI diagnosis for Sarah Miller according to EASL guidelines?\n\n\n# Context\n\n## Patient Profile\n- Name: Sarah Miller\n- Age/Sex: 63-year-old female\n- Primary Diagnoses: Rheumatoid arthritis, Essential hypertension, Mild chronic kidney disease\n- Risk Level: High\n- EASL Relevance: High risk due to age, female sex, RA, CKD, chronic MTX use, and recent TMP-SMX.\n\n## Relevant Timeline\n| Date | Event | Diagnosis/Note | Medications | Clinical Comment |\n|------|--------|----------------|--------------|------------------|\n| 2015-08-10 | Rheumatology Initial Consult | Seropositive Rheumatoid Arthritis (active) | Methotrexate 10mg weekly, Folic Acid 5mg weekly | Started MTX therapy with folic acid supplementation |\n| 2016-02-20 | General Practice | Stable RA on MTX | Methotrexate 10mg weekly, Folic Acid 5mg weekly | Good RA control on MTX; no MTX side effects |\n| 2018-09-05 | General Practice | New essential hypertension; RA stable; plan MTX dose increase | Methotrexate 20mg weekly, Folic Acid 5mg weekly, Lisinopril 10mg daily | MTX increased to 20mg due to mild flares |\n|\n...truncated\n\n# Short Answer\nSarah Miller's clinical presentation and lab results meet the EASL guidelines for **Severe Idiosyncratic Hepatocellular Drug-Induced Liver Injury (DILI)**. The most likely causative agent is trimethoprim-sulfamethoxazole (TMP-SMX), given the acute onset of severe liver injury six days after its initiation. Her age, female sex, and chronic methotrexate use are contributing risk factors.\n\n# Detailed Answer\nSarah Miller's lab results show ALT 1650 U/L, AST 2100 U/L, Total Bilirubin 12.5 mg/dL, and Alk Phos 350 U/L. Using common Upper Limit of Normal (ULN) values (ALT ~40 U/L, AST ~40 U/L, ALP ~120 U/L, Total Bilirubin ~1.2 mg/dL), her ALT is 41.25 ULN, AST is 52.5 ULN, ALP is 2.92 ULN, and Total Bilirubin is 10.42 ULN.\n\n    According to EASL guidelines, DILI is confirmed by an ALT elevation ≥5 ULN, which Sarah's ALT of 41.25 ULN clearly exceeds . To determine the DILI pattern, the R ratio (ALT/ULN / ALP/ULN) is calculated. Sarah's R ratio is 41.25 / 2.92 ≈ 14.1. Since R ≥ 5, the DILI pattern is **hepatocellular** .\n\n    For severity, Sarah's Total Bilirubin of 12.5 mg/dL is significantly ≥2.5 mg/dL, and she presents with confusion and suspected hepatic encephalopathy. The US DILIN severity classification defines **Severe DILI** (Category 4) as elevated ALT and/or ALP and TBL ≥2.5 mg/dL, and at least one of the following: hepatic failure (INR ≥1.5, ascites or encephalopathy) or other organ failure due to DILI . Although her INR is normal (1), the presence of encephalopathy is sufficient for this classification. The International DILI Expert Working Group also classifies this as Severe DILI (Category 3) due to ALT ≥5 ULN, TBL ≥2 ULN, and encephalopathy .\n\n    The most likely causative agent is **trimethoprim-sulfamethoxazole (TMP-SMX)**. This antibiotic was initiated six days prior to the onset of liver injury, fitting the typical latency period of days to weeks for idiosyncratic DILI . Co-trimoxazole (TMP-SMX) and sulfonamides are explicitly listed as antimicrobials associated with idiosyncratic DILI, and retrospective studies have identified TMP-SMX as a commonly implicated agent . While chronic methotrexate use and lisinopril are also associated with idiosyncratic DILI, their long-term use makes them less likely to be the primary cause of this acute, severe presentation, though methotrexate could predispose her to injury. Sarah's age (63 years) and female sex are recognized risk factors for DILI .\n\n# References\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Retrospective Studies\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic DILI\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Alcohol and Pregnancy\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes\n",
    "color": "#ffffff",
    "rotation": 0,
    "agentData": {
        "title": "EASL Answer",
        "markdown": "# Question\nSarah Miller, a 63-year-old female with a history of rheumatoid arthritis treated with methotrexate 20mg weekly since 2015, hypertension managed with lisinopril 10mg daily, and mild chronic kidney disease, presented to the emergency department with a 24-hour history of jaundice, confusion, and epigastric pain. She had been started on trimethoprim-sulfamethoxazole 800/160mg BID six days prior for acute bacterial sinusitis. Lab results revealed ALT 1650 U/L, AST 2100 U/L, total bilirubin 12.5 mg/dL, and direct bilirubin 8.9 mg/dL. What is the DILI diagnosis for Sarah Miller according to EASL guidelines?\n\n\n# Context\n\n## Patient Profile\n- Name: Sarah Miller\n- Age/Sex: 63-year-old female\n- Primary Diagnoses: Rheumatoid arthritis, Essential hypertension, Mild chronic kidney disease\n- Risk Level: High\n- EASL Relevance: High risk due to age, female sex, RA, CKD, chronic MTX use, and recent TMP-SMX.\n\n## Relevant Timeline\n| Date | Event | Diagnosis/Note | Medications | Clinical Comment |\n|------|--------|----------------|--------------|------------------|\n| 2015-08-10 | Rheumatology Initial Consult | Seropositive Rheumatoid Arthritis (active) | Methotrexate 10mg weekly, Folic Acid 5mg weekly | Started MTX therapy with folic acid supplementation |\n| 2016-02-20 | General Practice | Stable RA on MTX | Methotrexate 10mg weekly, Folic Acid 5mg weekly | Good RA control on MTX; no MTX side effects |\n| 2018-09-05 | General Practice | New essential hypertension; RA stable; plan MTX dose increase | Methotrexate 20mg weekly, Folic Acid 5mg weekly, Lisinopril 10mg daily | MTX increased to 20mg due to mild flares |\n|\n...truncated\n\n# Short Answer\nSarah Miller's clinical presentation and lab results meet the EASL guidelines for **Severe Idiosyncratic Hepatocellular Drug-Induced Liver Injury (DILI)**. The most likely causative agent is trimethoprim-sulfamethoxazole (TMP-SMX), given the acute onset of severe liver injury six days after its initiation. Her age, female sex, and chronic methotrexate use are contributing risk factors.\n\n# Detailed Answer\nSarah Miller's lab results show ALT 1650 U/L, AST 2100 U/L, Total Bilirubin 12.5 mg/dL, and Alk Phos 350 U/L. Using common Upper Limit of Normal (ULN) values (ALT ~40 U/L, AST ~40 U/L, ALP ~120 U/L, Total Bilirubin ~1.2 mg/dL), her ALT is 41.25 ULN, AST is 52.5 ULN, ALP is 2.92 ULN, and Total Bilirubin is 10.42 ULN.\n\n    According to EASL guidelines, DILI is confirmed by an ALT elevation ≥5 ULN, which Sarah's ALT of 41.25 ULN clearly exceeds . To determine the DILI pattern, the R ratio (ALT/ULN / ALP/ULN) is calculated. Sarah's R ratio is 41.25 / 2.92 ≈ 14.1. Since R ≥ 5, the DILI pattern is **hepatocellular** .\n\n    For severity, Sarah's Total Bilirubin of 12.5 mg/dL is significantly ≥2.5 mg/dL, and she presents with confusion and suspected hepatic encephalopathy. The US DILIN severity classification defines **Severe DILI** (Category 4) as elevated ALT and/or ALP and TBL ≥2.5 mg/dL, and at least one of the following: hepatic failure (INR ≥1.5, ascites or encephalopathy) or other organ failure due to DILI . Although her INR is normal (1), the presence of encephalopathy is sufficient for this classification. The International DILI Expert Working Group also classifies this as Severe DILI (Category 3) due to ALT ≥5 ULN, TBL ≥2 ULN, and encephalopathy .\n\n    The most likely causative agent is **trimethoprim-sulfamethoxazole (TMP-SMX)**. This antibiotic was initiated six days prior to the onset of liver injury, fitting the typical latency period of days to weeks for idiosyncratic DILI . Co-trimoxazole (TMP-SMX) and sulfonamides are explicitly listed as antimicrobials associated with idiosyncratic DILI, and retrospective studies have identified TMP-SMX as a commonly implicated agent . While chronic methotrexate use and lisinopril are also associated with idiosyncratic DILI, their long-term use makes them less likely to be the primary cause of this acute, severe presentation, though methotrexate could predispose her to injury. Sarah's age (63 years) and female sex are recognized risk factors for DILI .\n\n# References\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Patterns of DILI\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Retrospective Studies\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Chronic DILI\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Introduction to DILI Classification\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Alcohol and Pregnancy\n- EASL Clinical Practice Guidelines: Drug-induced liver injury-Laboratory Workup for Excluding Alternative Causes\n"
    },
    "createdAt": "2025-11-05T11:53:51.631Z",
    "updatedAt": "2025-11-05T11:53:51.631Z"
}